

NOVEN PHARMACEUTICALS INC

Form 8-K

July 29, 2004

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (date of earliest event reported): July 29, 2004

Noven Pharmaceuticals, Inc.

11960 S.W. 144th Street, Miami, Florida 33186

305-253-5099

Incorporated under the laws of
the
State of Delaware

Commission File Number
0-17254

I.R.S. Employer Identification
Number
59-2767632

Table of Contents

TABLE OF CONTENTS

Item 7. Exhibits

Item 12. Results of Operations and Financial Condition

SIGNATURES

INDEX TO EXHIBITS

Exhibit 99.1

Press Release

Table of Contents

Item 7. Exhibits

(c) Exhibits.

- 99.1 Press release dated July 29, 2004 announcing the financial results of Noven Pharmaceuticals, Inc. for the quarter ended June 30, 2004.

Item 12. Results of Operations and Financial Condition

On July 29, 2004, Noven issued a press release announcing its financial results for the quarter ended June 30, 2004. This press release, a copy of which is attached hereto as Exhibit 99.1, is furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or incorporated by reference into a filing under the Securities Act of 1933 or the Exchange Act.

-2-

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

NOVEN PHARMACEUTICALS, INC.

/s/ Jeffrey F. Eisenberg
Jeffrey F. Eisenberg
Vice President, General Counsel and
Corporate Secretary

Date: July 29, 2004

-3-

Table of Contents

INDEX TO EXHIBITS

<u>Exhibit No.</u>	<u>Description</u>
---------------------------	---------------------------

99.1	Press Release, dated July 29, 2004, announcing the financial results of Noven Pharmaceuticals, Inc. for the quarter ended June 30, 2004
------	---

-4-